Market closed
NeuroSense Therapeutics Ltd./$NRSN
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.
Ticker
$NRSN
Sector
Trading on
Industry
Biotechnology
Headquarters
Herzliya, Israel
Employees
17
ISIN
IL0011809592
Website
NRSN Metrics
BasicAdvanced
$25M
-
-$0.55
1.35
-
Price and volume
Market cap
$25M
Beta
1.35
52-week high
$1.23
52-week low
$0.85
Average daily volume
120K
Financial strength
Current ratio
2.21
Quick ratio
2.192
Total debt to equity
2.826
Interest coverage (TTM)
-32.15%
Management effectiveness
Return on assets (TTM)
-159.50%
Return on equity (TTM)
-2,478.16%
Valuation
Price to book
9.44
Price to tangible book (TTM)
9.44
Price to free cash flow (TTM)
-1.926
Growth
Earnings per share change (TTM)
-25.93%
3-year earnings per share growth (CAGR)
2.10%
NRSN News
AllArticlesVideos
Market Alert: NeuroSense Therapeutics Advances Toward Early Canadian Commercialization of ALS Drug
Business Wire·2 months ago
PESG Releases Report on NeuroSense Therapeutics: Groundbreaking ALS Therapy Signals Massive Potential Opportunity in Billion Dollar Treatment Landscape
Business Wire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for NeuroSense Therapeutics Ltd. stock?
NeuroSense Therapeutics Ltd. (NRSN) has a market cap of $25M as of May 10, 2025.
What is the P/E ratio for NeuroSense Therapeutics Ltd. stock?
The price to earnings (P/E) ratio for NeuroSense Therapeutics Ltd. (NRSN) stock is 0 as of May 10, 2025.
Does NeuroSense Therapeutics Ltd. stock pay dividends?
No, NeuroSense Therapeutics Ltd. (NRSN) stock does not pay dividends to its shareholders as of May 10, 2025.
When is the next NeuroSense Therapeutics Ltd. dividend payment date?
NeuroSense Therapeutics Ltd. (NRSN) stock does not pay dividends to its shareholders.
What is the beta indicator for NeuroSense Therapeutics Ltd.?
NeuroSense Therapeutics Ltd. (NRSN) has a beta rating of 1.35. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.